Diabetic retinopathy

Diabetic retinopathy is a chronic microvascular and neurovascular complication of diabetes mellitus that affects the retina and arises from prolonged exposure of retinal tissue to hyperglycemia, hemodynamic abnormalities, and the systemic inflammatory-metabolic environment typical of diabetes. In the modern view, it is no longer considered merely a simple microangiopathy, but a true disease of the retinal neurovascular unit, in which endothelial cells, pericytes, neurons, glial cells, and the blood-retinal barrier undergo progressive dysfunctional remodeling. The final result is increased vascular permeability, capillary occlusion, retinal ischemia, macular edema, and, in advanced forms, pathological neovascularization with a risk of vitreous hemorrhage and tractional retinal detachment.

Its clinical relevance is enormous because it is one of the leading causes of visual impairment and preventable blindness in adults with diabetes. The probability of developing retinopathy increases with diabetes duration, the degree of glycemic control, and the presence of other systemic risk factors, but its natural history is extremely heterogeneous: some patients maintain minimal or stable forms for a long time, whereas others progress more rapidly toward sight-threatening disease. This variability depends on the interaction among cumulative glycemic burden, blood pressure, kidney function, lipid profile, pregnancy, individual susceptibility, and the intensity of local inflammatory and angiogenic mechanisms.

Epidemiologically, diabetic retinopathy affects approximately one fifth of the global population with diabetes, whereas vision-threatening forms—those truly associated with risk of visual loss, such as clinically significant diabetic macular edema or proliferative retinopathy—represent a smaller but still very substantial absolute burden. Recent estimates indicate a global prevalence of any diabetic retinopathy of about 22%, sight-threatening forms of about 6%, and clinically significant macular edema of about 4%, with a projected further increase in disease burden over the coming decades as diabetes becomes more common worldwide. Historical cohorts with very long follow-up have shown extremely high lifetime progression, confirming that diabetic retinopathy is closely related to the duration of metabolic exposure and that regular screening remains crucial even in the absence of symptoms.

The definite etiological cause of diabetic retinopathy is diabetes mellitus, namely chronic retinal exposure to an altered metabolic environment dominated by hyperglycemia. This apparently simple statement must be understood in depth: retinopathy is not generated by a single elevated blood glucose value, but by cumulative injury over time from glycemic fluctuations, the overall glucotoxic burden, oxidative stress, endothelial dysfunction, and hemorheological abnormalities. Diabetes duration is therefore one of the strongest determinants of risk because it indirectly but faithfully represents the period during which the retina has been exposed to these biological insults. In type 1 diabetes, risk becomes clinically relevant after several years of disease, whereas in type 2 diabetes retinopathy may already be present at diagnosis because the preceding asymptomatic phase may be prolonged and biologically active.

Alongside the etiological cause are numerous risk factors that modulate onset and, above all, progression. The most firmly documented are chronically poor glycemic control, arterial hypertension, diabetic nephropathy with albuminuria or reduced glomerular filtration rate, dyslipidemia, pregnancy in women with pre-existing diabetes, and rapid correction of marked hyperglycemia in individuals with established retinopathy. Puberty, anemia, and some states of increased systemic stress also appear to promote greater instability. The relationship with smoking is less straightforward than for other vascular complications, but the patient's overall systemic context, including the quality of blood pressure, renal, and metabolic control, remains fundamental in defining the disease trajectory.

Pathogenic damage begins early in the retinal microcirculation. Chronic hyperglycemia activates the polyol pathway with intracellular sorbitol accumulation, consumes NADPH, and reduces cellular antioxidant capacity; at the same time it promotes formation of advanced glycation end products, alters intracellular signaling through protein kinase C activation, increases flux through the hexosamine pathway, and amplifies mitochondrial production of reactive oxygen species. These mechanisms do not act in isolation but reinforce one another, creating a toxic environment for endothelial cells, pericytes, and glial cells. Pericytes, which are essential for capillary stability, undergo early apoptosis; the basement membrane thickens; tight junctions of the inner blood-retinal barrier lose integrity; the capillary wall becomes fragile; and microaneurysms appear, representing the first clinically visible sign of disease in many patients.

In parallel, an increasingly important inflammatory component develops. The diabetic retina expresses adhesion molecules, particularly ICAM-1, that promote leukostasis, namely adhesion and slowing of leukocytes within the microcirculation. The result is capillary micro-occlusion with further endothelial injury, increased permeability, and worsening tissue ischemia. Cytokines and mediators such as tumor necrosis factor alpha, proinflammatory interleukins, chemokines, and vasoactive factors amplify vascular dysfunction. Müller cells and microglia are activated early and contribute to maintaining a state of chronic neuroinflammation. Diabetic retinopathy is therefore now interpreted as a disease in which microvascular and neurodegenerative components progress in parallel from the earliest stages.

From a pathophysiological standpoint, a central step is loss of homeostasis of the blood-retinal barrier. When the barrier loses selectivity, plasma, proteins, and lipids escape from the vascular bed into the retinal parenchyma. This causes retinal edema and formation of hard exudates, which are residual lipoprotein deposits from chronic leakage. When this process involves the macular region, particularly the center, diabetic macular edema develops and becomes one of the leading causes of visual impairment in people with diabetes. Edema may be focal, when leaking microaneurysms and circumscribed leakage points predominate, or more diffuse, when generalized impairment of the capillary barrier prevails. In some eyes, the condition is aggravated by vitreomacular traction or an epiretinal membrane, which increases mechanical stress on the macula.

A second fundamental pathophysiological axis is retinal ischemia. Progressive capillary closure produces areas of nonperfusion, initially microscopic and then increasingly extensive. Clinically, this is reflected by more widespread intraretinal hemorrhages, cotton-wool spots representing microinfarctions of the nerve fiber layer, irregular venous loops, venous beading, and intraretinal microvascular abnormalities, or IRMAs, which indicate an ischemic and remodeled retina. When ischemia becomes extensive, the hypoxic retina increases production of HIF-1α, VEGF, and other proangiogenic mediators, among which the angiopoietin-2/Tie2 system has gained increasing importance. The result is the development of fragile and biologically unstable new vessels on the optic disc or elsewhere, which cannot restore physiological perfusion and instead cause further complications.

Proliferative retinopathy is the stage in which the pathological angiogenic response dominates the clinical picture. New vessels grow on the retinal surface and into the posterior vitreous, are associated with fibroglial tissue, bleed easily, and may organize into contractile fibrovascular membranes. This sequence causes preretinal hemorrhage, vitreous hemorrhage, and tractional retinal detachment. If ischemia involves the anterior segment, the angiogenic drive may extend to the iris and anterior chamber angle, inducing iris rubeosis and neovascular glaucoma, one of the most destructive complications of the entire disease.

The pathophysiology of vision loss is therefore not uniform. A patient may have reduced vision because of macular edema, macular ischemia, vitreous hemorrhage, tractional detachment, neovascular glaucoma, or chronic neuroretinal damage that reduces contrast sensitivity and visual quality even before a marked decline in central visual acuity. This distinction is essential because it explains why patients with apparently similar retinas on fundoscopy may have very different visual function and why anatomical drying of the macula does not always correspond to full visual recovery, particularly when photoreceptor damage or foveal ischemia is already advanced.

The phenomenon of early worsening of retinopathy after a rapid reduction in glycated hemoglobin deserves specific mention. Intensive glycemic control remains one of the pillars of long-term prevention of retinopathy, but in some patients with severe long-standing hyperglycemia and pre-existing retinopathy, an excessively rapid improvement in glycemic control may be associated with temporary acceleration of retinal damage or progression of ocular disease. This does not negate the benefit of good metabolic control, but requires a more refined clinical approach: metabolic improvement should be pursued with awareness of the baseline retinal status and with appropriate ophthalmologic follow-up in patients at highest risk.

The clinical manifestations of diabetic retinopathy depend on disease stage and, above all, on the mechanism by which retinal damage interferes with visual function. In the early stages, the patient is very often asymptomatic. This is crucial in clinical practice because it explains why diagnosis is frequently made through screening rather than after subjective symptoms appear. The peripheral retina may accumulate numerous lesions without the patient noticing, and even moderate or severe nonproliferative retinopathy may remain silent for a long time if the macula is not involved and no vitreous hemorrhage occurs.

When symptoms appear, the patient most often reports progressive or fluctuating blurred vision, difficulty reading, a sense that images are less sharp, reduced contrast perception, and sometimes metamorphopsia, particularly when macular edema is present. With substantial macular involvement, central vision may become less defined, lines may appear distorted, and visual quality may be worse in low-light conditions. In other cases, the main complaint is vision that varies during the day, a phenomenon to which glycemic fluctuations with transient refractive changes may also contribute.

When the disease progresses to the proliferative stage, symptoms may change abruptly. The onset of floaters, moving shadows, dark strands, or a “shower of soot” in the visual field suggests preretinal or vitreous bleeding. If the hemorrhage is more substantial, the patient may describe sudden partial or nearly complete visual loss, sometimes on awakening. If fibrovascular traction predominates, the patient may perceive image distortion, a fixed dark area, or progressive visual loss; when tractional detachment involves or threatens the macula, visual impairment becomes more pronounced and often more irreversible.

The ophthalmologic examination begins with best-corrected visual acuity, pupillary assessment, tonometry, and slit-lamp examination of the anterior segment. This phase may already reveal important findings. An associated cataract may reduce vision and make fundus examination more difficult; iris rubeosis is a warning sign of severe retinal ischemia and risk of neovascular glaucoma; and increased intraocular pressure may indicate that the angiogenic process has already involved the anterior chamber angle. Dilated fundus examination then allows reconstruction of the morphological sequence of the disease.

In mild nonproliferative retinopathy, the most typical finding is microaneurysms, small deep red dots corresponding to saccular dilatations of the capillary wall. As damage worsens, dot-and-blot intraretinal hemorrhages, hard exudates, cotton-wool spots, venous dilatations or irregularities, and intraretinal microvascular abnormalities appear. Their distribution and burden indicate the extent to which the retina is entering an ischemia-dominated phase. Venous beading and IRMAs in particular are signs of marked biological instability and increased risk of progression to proliferative disease.

When diabetic macular edema is present, examination of the posterior pole may reveal retinal thickening, loss of the normal foveal reflex, circinate hard exudates, and, in more advanced cases, complex structural abnormalities. Clinical observation alone, however, is not always sufficient to define the extent of edema because some damage is better captured by imaging techniques. Visual loss may also be caused by diabetic macular ischemia rather than true edema; in such cases, the fundus may appear less striking than the functional deficit would suggest.

In proliferative disease, neovascularization is observed on the optic disc or elsewhere in the retina, together with preretinal hemorrhage, vitreous hemorrhage, and fibrovascular membranes. As these membranes contract, the retina is elevated and distorted. The fundus may then progress from simple superficial neovascularization to obvious traction, with retinal folds, anatomical distortion of the posterior pole, and threatened macular involvement. In extreme cases, patients may present with a picture dominated more by end-stage complications than by the underlying lesions.

The temporal relationship between symptoms and lesions is therefore highly variable. Advanced retinopathy may remain surprisingly minimally symptomatic until a complication occurs, whereas relatively limited macular edema in a critical location may substantially impair reading and near-work ability. In real-world practice, the absence of symptoms is therefore never reassuring in a patient with diabetes and must never replace scheduled monitoring.

Diagnosis of diabetic retinopathy begins with recognition of risk and culminates in precise definition of disease stage, macular involvement, and the eye's prognostic profile. In practice, the possibility must be considered in every patient with diabetes, even if completely asymptomatic. Guidelines therefore recommend structured ophthalmologic screening: in type 1 diabetes, the first assessment should be performed within 5 years of onset, whereas in type 2 diabetes it should be performed at diagnosis because retinal disease may precede clinical recognition of diabetes itself. In women with pre-existing diabetes who are planning pregnancy or are already in the first trimester, ophthalmologic examination is even more important and should be performed early, with more frequent monitoring during pregnancy and postpartum according to disease severity.

The first diagnostic level is dilated fundus examination, which remains the fundamental clinical reference, or fundus photography performed with validated systems within organized pathways that ensure specialist interpretation and management of positive or ungradable results. Diagnosis is not based on a single blood biomarker or indirect test, but on recognition of a typical lesion pattern in a patient with diabetes. In other words, diagnosis is clinical and instrumental, based on identification of retinal lesions attributable to diabetes and their correct classification.

Once lesions have been documented, the next step is grading the retinopathy. An internationally shared clinical classification is available and is highly useful because it translates morphological findings into severity categories with clear prognostic significance. Nonproliferative forms are divided into mild, moderate, and severe, whereas neovascularization or preretinal or vitreous hemorrhage defines proliferative retinopathy. In practice, this classification is not merely descriptive: it estimates the risk of progression and guides follow-up frequency and the timing of therapeutic intervention.

Diabetic retinopathy grading (ETDRS criteria)

• No apparent retinopathy: no visible lesion attributable to diabetes.
• Mild nonproliferative retinopathy: microaneurysms only.
• Moderate nonproliferative retinopathy: lesions more extensive than microaneurysms alone but insufficient for severe disease.
• Severe nonproliferative retinopathy: the 4-2-1 rule, namely marked intraretinal hemorrhages and microaneurysms in 4 quadrants, or venous beading in at least 2 quadrants, or prominent IRMAs in at least 1 quadrant, without proliferative signs.
• Proliferative retinopathy: neovascularization and/or preretinal or vitreous hemorrhage.

In addition to retinopathy severity, macular status must always be defined. Diabetic macular edema may be described clinically as absent or present; when examination permits, severity can be further graded according to the distance of retinal thickening or hard exudates from the macular center. In contemporary practice, however, the true diagnostic breakthrough is optical coherence tomography (OCT), which is essential for quantifying retinal thickness, visualizing cystoid spaces, subretinal fluid, abnormalities of the vitreomacular interface, and monitoring treatment response. According to the most recent recommendations, OCT should be used whenever diabetic macular edema is evaluated or followed. The concept of center-involving macular edema derives specifically from involvement of the central 1-mm subfield of the ETDRS grid and has immediate therapeutic implications.

Classification of diabetic macular edema (DME)

• Clinically significant diabetic macular edema: retinal thickening within 500 micrometers of the foveal center, or hard exudates within 500 micrometers of the center associated with adjacent retinal thickening, or an area of thickening at least one disc area in size located within one disc diameter of the macular center.
• Center-involving macular edema: involvement of the central subfield on OCT.

When clinical and tomographic documentation alone is insufficient, second-level investigations are used. Fluorescein angiography retains an important role when it is necessary to clarify the cause of visual loss, distinguish edema from ischemia, identify focal leakage, document subtle neovascularization, or plan laser treatment. It is also particularly useful for studying ischemic maculopathy, in which visual damage may be severe despite unimpressive edema. Angiography is not required in every patient, but it is valuable when the clinical question is specific and the result may alter the therapeutic decision.

OCT angiography allows noninvasive visualization of the retinal capillary plexuses and foveal avascular zone, providing increasingly sophisticated information on macular perfusion and vascular rarefaction. However, it does not completely replace fluorescein angiography because it does not demonstrate leakage according to the same pathophysiological logic. It is therefore a complementary and highly promising examination, particularly for characterization of macular ischemia and subclinical microvascular abnormalities, but it must always be interpreted within the overall clinical context.

Ultra-widefield imaging may add relevant information in peripheral or proliferative forms because it more readily documents areas of ischemia and lesions remote from the posterior pole. Recent guidelines recognize its usefulness as an adjunct to clinical examination, particularly in the assessment of proliferative retinopathy. If the ocular media are opaque and the vitreous is filled with blood, B-scan ocular ultrasonography becomes essential to exclude or confirm tractional retinal detachment and define the posterior segment when the fundus cannot be visualized.

The differential diagnosis must always be considered, especially when lesion distribution is atypical, the picture is markedly asymmetric, or the patient's diabetic history is inconsistent with the severity of the findings. Depending on the case, hypertensive retinopathy, retinal vein occlusion, ocular ischemic syndrome, radiation retinopathy, retinal vasculitis, certain hemoglobinopathies, and other exudative maculopathies must be excluded. The correct principle is that diabetic retinopathy is diagnosed when the findings are compatible with diabetes and the clinical context makes this the most plausible interpretation; when something does not fit, the diagnostic label should not be applied automatically.

Finally, diagnostic assessment is incomplete unless it also includes the organs and systemic factors that influence the retina. Glycated hemoglobin, blood pressure, kidney function with albuminuria and glomerular filtration rate, lipid profile, possible pregnancy, and the patient's treatment profile are integral to diagnostic reasoning because they explain the rate of progression, the risk of worsening, and the potential for stabilization. In this sense, diagnosis of diabetic retinopathy is not merely an ocular diagnosis: it is the ophthalmologic interpretation of a complex systemic disease.

Treatment of diabetic retinopathy always requires a dual systemic and ocular strategy. The first corrects the biological determinants of disease, while the second directly treats retinal complications responsible for visual risk. Neither is sufficient alone. Improving glycemic, blood pressure, and lipid control reduces incidence and slows progression of retinopathy, but does not replace ocular treatment once macular edema or proliferation is present. Similarly, intravitreal injection or laser therapy may preserve visual function in an eye, but is less effective and less durable if the patient remains in a strongly unfavorable systemic metabolic environment.

The rationale for intensive metabolic control is supported by decisive landmark studies. In type 1 diabetes, intensive therapy has been shown to reduce the onset and progression of retinopathy and to leave a favorable form of metabolic memory over time even as glycemic differences diminish. In type 2 diabetes, blood pressure and glycemic control likewise have a documented impact on the natural history of the disease. Clinical practice must nevertheless remember that rapid correction of very severe hyperglycemia, particularly in individuals with already significant retinopathy, may be associated with temporary early worsening of the ocular condition. This is not a contraindication to treating diabetes, but it requires closer monitoring and greater interpretive caution.

In the early stages—mild or moderate nonproliferative retinopathy without visually significant macular edema—the main treatment is systemic optimization combined with scheduled observation. This does not mean “doing nothing,” but preventing progression by reducing the biological risk burden and organizing follow-up appropriate to disease stage. Follow-up becomes more frequent as the condition approaches severe nonproliferative disease because the risk of conversion to proliferative retinopathy increases substantially.

Management is more complex in severe or very severe nonproliferative retinopathy without macular edema. Historically, these patients were primarily monitored closely until proliferative signs appeared, but the availability of intravitreal anti-VEGF agents has created a different scenario. Recent studies have shown that VEGF inhibition in severe nonproliferative retinopathy can improve retinopathy severity and reduce the short- to medium-term risk of vision-threatening complications. This benefit must, however, be balanced against treatment burden, the need for long-term adherence, and the fact that discontinuation may reduce the stability of the benefit achieved. Preventive anti-VEGF therapy in severe nonproliferative disease should therefore not be regarded as automatically mandatory for everyone, but should form part of an individualized risk assessment.

When the main problem is diabetic macular edema, treatment depends on center involvement and visual impact. In center-involving forms with visual impairment, intravitreal anti-VEGF agents are first-line therapy in most cases. Aflibercept, ranibizumab, and faricimab are supported by randomized trials, whereas bevacizumab is widely used in many clinical settings because of accessibility and cost, although its regulatory status varies by country and indication. Drug selection is not merely theoretical: baseline visual acuity, edema severity, the expected response profile, logistical sustainability of repeated injections, the patient's willingness to attend frequent visits, and cofactors such as pseudophakia, pressure-related risk, or previous poor response all matter.

Comparative evidence has shown that all major anti-VEGF agents improve vision in diabetic macular edema, but differences among molecules may emerge in patients with worse baseline visual acuity. In practice, this means that drug selection should be based not only on habit, but on the clinical phenotype. More recently, faricimab, through dual inhibition of VEGF-A and angiopoietin-2, has demonstrated the possibility of maintaining visual efficacy with longer treatment intervals in a substantial proportion of patients, a highly relevant feature in real-world management of chronic disease.

If the response to anti-VEGF therapy is partial or inadequate, the reason must be investigated. In some cases, edema has a strong inflammatory component; in others, vitreomacular traction predominates; in still others, macular ischemia limits functional gain despite anatomical improvement. In these settings, it may be reasonable to switch agents, add or reintroduce macular laser, or move to an intravitreal corticosteroid implant, particularly in pseudophakic patients or those for whom adherence to very frequent injections is problematic. Corticosteroids have a genuine role, but their limitations must be fully recognized: they increase the risk of cataract and ocular hypertension, so patients must be selected carefully.

In center-involving diabetic macular edema with good visual acuity, more recent evidence has challenged the idea that every central edema requires immediate injection therapy. In selected cases, close observation or laser treatment may be appropriate, provided follow-up is rigorous and the patient is reliable. Conversely, when edema is non-center-involving but clinically significant, focal or grid laser retains a role, particularly as a stabilizing treatment for specific leakage patterns.

Proliferative retinopathy remains the setting in which therapeutic choice has the most immediate prognostic implications. Panretinal photocoagulation remains a fundamental treatment and is the reference strategy for many patients. Its rationale is to reduce the ischemic and angiogenic drive by ablating ischemic peripheral retina, thereby inducing regression of neovascularization and markedly reducing the risk of vitreous hemorrhage and severe blindness. Recent guidelines emphasize that panretinal photocoagulation should be offered promptly to most patients with proliferative retinopathy, with particular urgency in high-risk disease or when the patient is unlikely to adhere to follow-up. Its main advantage is durability; its disadvantages are potential reduction of peripheral visual field, worsening of night vision, reduced contrast sensitivity, and, in some cases, temporary exacerbation of macular edema.

Anti-VEGF agents have been shown to be noninferior to laser in some settings of proliferative retinopathy and are now a highly valid alternative or adjunct, especially when diabetic macular edema coexists. The crucial issue, however, is adherence: proliferation regresses while VEGF is adequately suppressed, but patients who miss visits or discontinue treatment may have a meaningful risk of reactivation. In real-world practice, laser therefore retains an importance that extends beyond numerical trial comparisons because it offers greater protection for patients with poor adherence. When vitreous hemorrhage prevents laser treatment, anti-VEGF therapy may be used as a temporary bridge, but it should not automatically become an indefinite postponement of definitive treatment when the latter is indicated.

Pars plana vitrectomy is used when disease has progressed beyond what can be managed with medical therapy or laser alone. Classic indications include nonclearing vitreous hemorrhage, tractional retinal detachment threatening or involving the macula, certain combined tractional-rhegmatogenous forms, and cases of macular edema with marked vitreomacular traction or an unresponsive epiretinal membrane. Surgery permits removal of blood, pathological vitreous, and fibrovascular membranes, application of endolaser, and restoration of more favorable anatomical conditions. Visual outcome, however, depends greatly on how long the macula has been compromised and on the presence or absence of macular ischemia or irreversible photoreceptor damage.

A particular topic is the role of fenofibrate in type 2 diabetes with nonproliferative retinopathy. Some evidence has shown a favorable effect on retinopathy progression that is at least partly independent of triglyceride improvement, to the extent that recent guidelines consider its use in selected patients with nonproliferative disease. It is not a substitute for ocular treatment, but an additional systemic measure in an appropriate subgroup.

The prognosis of diabetic retinopathy depends on the stage at recognition and the timeliness of care. Early forms may remain stable for years or even partially regress with improvement of the systemic environment. Diabetic macular edema treated early now has a much better prognosis than in the pre-anti-VEGF era. Proliferative retinopathy, if detected before major hemorrhagic or tractional complications, can be effectively controlled with laser, intravitreal agents, or combined approaches. Prognosis worsens with advanced macular ischemia, recurrent vitreous hemorrhage, macula-involving tractional detachment, neovascular glaucoma, severely impaired kidney function, and poor adherence to follow-up. In summary, not all diabetic retinopathy is reversible, but much blindness is now preventable when the disease is recognized, classified, and treated before the structurally destructive stage.

The complications of diabetic retinopathy arise directly from the two major mechanisms governing the disease: breakdown of the blood-retinal barrier with edema, and ischemia with neovascularization. The most frequent cause of persistent visual impairment before end-stage disease is diabetic macular edema. Its danger depends not only on the amount of fluid, but above all on its location, chronicity, and toxic effect on neurosensory tissue. Persistent edema disrupts foveal architecture, damages photoreceptors, promotes subcentral lipid deposits, and may leave incomplete functional recovery even after apparent anatomical improvement.

A second major complication is ischemic maculopathy. In this condition, the central retina loses perfusion and visual impairment may be disproportionate to the amount of edema or may even occur without significant edema. The clinical problem is that ischemic maculopathy has less potential for functional recovery because visual limitation results from loss of nourishment to neurosensory tissue rather than merely fluid accumulation. It is therefore one of the main explanations for patients whose macula becomes “dry” on OCT but who recover little visual acuity.

In proliferative forms, complications are often more dramatic. Vitreous hemorrhage occurs because pathological new vessels are fragile and easily rupture, often in response to minimal traction from the posterior vitreous on the retinal surface. The hemorrhage may be mild and resolve, but it may also be massive and suddenly obscure the fundus, causing substantial visual loss. Recurrence is not uncommon if the angiogenic drive is not controlled.

Fibrovascular proliferation may organize into membranes that contract and exert progressive traction on the retina. This causes tractional retinal detachment, a mechanical complication of ischemic-proliferative disease. Functional risk depends on the location of traction: damage may remain relatively limited while the macula is spared, but visual prognosis worsens sharply when traction reaches the posterior pole. In some cases, the process is further complicated by secondary retinal breaks and becomes a combined tractional-rhegmatogenous detachment, which is even more difficult to treat.

One of the most severe complications is neovascular glaucoma. With extensive retinal ischemia, angiogenic mediators diffuse toward the anterior segment and induce neovascularization of the iris and iridocorneal angle. These new vessels, accompanied by fibrovascular tissue, obstruct aqueous humor outflow, causing an often severe and painful rise in intraocular pressure. Neovascular glaucoma is devastating because it combines pre-existing retinal damage with secondary pressure-induced optic neuropathy and requires urgent treatment of the ischemic drive as well as control of intraocular pressure.

There are also less conspicuous functional complications that are highly relevant to quality of life. Even without a marked decline in central visual acuity, patients may develop loss of contrast sensitivity, impaired mesopic vision, reduced peripheral field after extensive laser treatment, difficulty reading, greater visual fatigue, and reduced driving safety. In practice, disability from diabetic retinopathy does not always correspond solely to central visual acuity.

Treatment-related complications must also be considered. Panretinal photocoagulation, although sight-saving, may reduce night vision, constrict the peripheral visual field, and temporarily worsen pre-existing macular edema. Intravitreal injections carry a low but real risk of endophthalmitis, transient elevation of intraocular pressure, sterile inflammation, and, with corticosteroids, more persistent cataract and ocular hypertension. Vitrectomy may be complicated by recurrent hemorrhage, cataract progression, iatrogenic retinal breaks, or the need for further procedures. These treatment complications do not diminish the value of therapy, but explain why clinical decisions must always be individualized and proportionate to the severity of the natural visual risk.

Finally, from a systemic standpoint, advanced diabetic retinopathy is never an isolated finding. It often indicates diffuse microvascular damage and is associated with nephropathy, neuropathy, and increased cardiovascular risk. In this sense, the retina functions as a biological window onto the patient's overall vascular disease burden. Severe or rapidly progressive retinopathy therefore requires not only effective ocular treatment, but also comprehensive systemic reassessment.